CircPTPN22 can be used as a potential diagnostic and prognostic marker for GC and can inhibit cell proliferation and metastasis through the competitive binding of miRNA to inhibit the EMT pathway.
As a biomarker for gastric cancer, circPTPN22 regulates the progression of gastric cancer through the EMT pathway.